DBV Technologies (DBVT) Income towards Parent Company (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Income towards Parent Company of -$50.4 million for Q2 2026, down 20.29% year-on-year from -$63.2 million in Q2 2025, and down 5.88% on a QoQ basis from -$47.6 million in Q1 2026.
DBV Technologies (DBVT) Income towards Parent Company (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Income towards Parent Company for 7 consecutive years, with -$50.4 million the latest figure, recorded in Q2 2026.
- Quarterly Income towards Parent Company fell 20.29% year-over-year to -$50.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$176.0 million (down 43.72% YoY) and the FY2025 annual result came in at -$146.9 million, down 28.99% from the prior year.
- Income towards Parent Company fell to -$50.4 million in Q2 2026 per DBVT's latest filing, from -$47.6 million in the prior quarter.
- Over the last five years, Income towards Parent Company for DBVT reached as high as -$11.2 million in Q4 2023 and fell as low as -$50.4 million in Q2 2026.
- A 5-year average of -$29.3 million and a median of -$27.2 million in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 187.02% — and 2023, when it jumped 71.49%.
- Year by year, Income towards Parent Company stood at -$39.2 million in 2022, then soared by 71.49% to -$11.2 million in 2023, then slumped by 105.75% to -$23.0 million in 2024, then slumped by 94.78% to -$44.8 million in 2025, then slipped by 12.43% to -$50.4 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$50.4 million, -$47.6 million, and -$44.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn |
| 10 | DBV Technologies | 5.99 Bn | 5.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.40 Mn |
| Mar 31, 2026 | -47.60 Mn |
| Dec 31, 2025 | -44.83 Mn |
| Sep 30, 2025 | -33.16 Mn |
| Jun 30, 2025 | -41.90 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Dec 31, 2024 | -23.02 Mn |
| Sep 30, 2024 | -30.44 Mn |
| Jun 30, 2024 | -33.12 Mn |
| Mar 31, 2024 | -27.35 Mn |
| Dec 31, 2023 | -11.19 Mn |
| Sep 30, 2023 | -16.74 Mn |
| Jun 30, 2023 | -24.24 Mn |
| Mar 31, 2023 | -20.56 Mn |
| Dec 31, 2022 | -39.24 Mn |
| Sep 30, 2022 | -17.29 Mn |
| Jun 30, 2022 | -23.04 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -13.67 Mn |
| Sep 30, 2021 | -24.03 Mn |